Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 2/20 | 0.60 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.60 |
| ▸ | ACHE | P22303 | 3/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | GBA1 | P04062 | 2/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9598465 | 0.95 | CHRM5 (0.67) | CHRM5ADRA2CACHESMN1; SMN2GBA1 | |
| SCHEMBL988572 | 0.88 | CHRM5 (0.48) | CHRM5ADRA2CACHESMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL11558196 | 0.86 | CHRM5 (0.46) | CHRM5ADRA2CACHESMN1; SMN2 | |
| SCHEMBL12204189 | 0.83 | CHRM5 (0.56) | CHRM5ADRA2CACHESMN1; SMN2GBA1 | |
| SCHEMBL18392104 | 0.83 | NCF1 (0.45) | CHRM5ADRA2CACHESMN1; SMN2KCNA3 | |
| SCHEMBL27097470 | 0.81 | CHRM5 (0.90) | CHRM5ADRA2CACHESMN1; SMN2OPRM1 | |
| SCHEMBL3156763 | 0.80 | CHRM5 (0.64) | CHRM5ADRA2CACHESMN1; SMN2GBA1 | |
| SCHEMBL13540687 | 0.78 | NCF1 (0.40) | CHRM5ADRA2CACHESMN1; SMN2OPRK1 | |
| SCHEMBL5648979 | 0.78 | GBA1 (0.50) | CHRM5ADRA2CACHESMN1; SMN2GBA1 | |
| SCHEMBL27544940 | 0.78 | SMN1; SMN2 (0.44) | CHRM5ADRA2CSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8198303-B2 | Methods of use and compositions for the diagnosis and treatment of infectious diseases | SEQUELLA, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-8198303-B2 | Methods of use and compositions for the diagnosis and treatment of infectious diseases | SEQUELLA, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-20100273826-A1 | METHODS OF USE AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF INFECTIOUS DISEASES | SEQUELLA, INC. | 2010-10-28 | — | — | US | disclosed |
| US-20100273826-A1 | METHODS OF USE AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF INFECTIOUS DISEASES | SEQUELLA, INC. | 2010-10-28 | — | — | US | disclosed |
| US-7652039-B2 | Such as 1-(2-((3-(4-chlorophenoxy)benzyl)amino)-3-phenyl-propyl)piperidin-4-ol for treatment of tuberculosis; solid phase synthesis | SEQUELLA, INC. (US) | 2010-01-26 | — | — | US | disclosed |
| US-7652039-B2 | Such as 1-(2-((3-(4-chlorophenoxy)benzyl)amino)-3-phenyl-propyl)piperidin-4-ol for treatment of tuberculosis; solid phase synthesis | SEQUELLA, INC. (US) | 2010-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273826-A1 | METHODS OF USE AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF INFECTIOUS DISEASES | C5, THPO, TERT | CHRM5 1490/4885ADRA2C 2328/4885ACHE 230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.